Correction: Kohsaka et al. Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. <i>J. Clin. Med.</i> 2022, <i>11</i>, 5828.

Kohsaka, Shun; Okami, Suguru; Morita, Naru; Yajima, Toshitaka

Correction: Kohsaka et al. Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828.

Kohsaka, Shun; Okami, Suguru; Morita, Naru; Yajima, Toshitaka.

Afiliação

Kohsaka S; Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Okami S; Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan.
Morita N; Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan.
Yajima T; Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan.

J Clin Med ; 12(7)2023 Mar 29.

Article em En | MEDLINE | ID: mdl-37048834

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google